Today: 19 April 2026
Santos Limited Stock Price Rises as $100 Oil and Moomba Project Boost Outlook
14 March 2026
1 min read

Santos Limited Stock Price Rises as $100 Oil and Moomba Project Boost Outlook

SYDNEY, March 14, 2026, 10:51 AEDT

Santos Ltd finished Friday 0.5% higher at A$7.53, boosted as oil prices shot back above the $100 mark. Brent closed out the week at $103.14—its first time crossing that threshold since August 2022—after another stretch of sharp swings in energy markets.

Santos stands out among Australian-listed companies with its direct exposure to firming crude and LNG prices. Energy stocks pushed up 1.1% on Friday, bucking the broader market’s decline amid inflation concerns and growing chatter about a possible Reserve Bank of Australia rate hike next week.

A company angle played into the broader move as well. Earlier this week, Santos and Beach Energy confirmed plans to move ahead with the Moomba Central Optimisation project in South Australia’s Cooper Basin. Santos is putting up about A$357 million for the project, which aims to squeeze more than A$600 million out of capital and operating savings and push unit costs down by as much as A$3 per barrel of oil equivalent—a metric that rolls oil and gas volumes together.

Chief Executive Kevin Gallagher described the plan as demonstrating “operational excellence and capital efficiency,” saying it should keep the Cooper Basin producing for longer. Santos added the project might trim its Scope 1 emissions—meaning its own operational pollution—by over 40,000 tonnes of carbon dioxide equivalent per year. Market Index Data API

Santos’s January update is still on investors’ desks. Back then, the company reported that Darwin LNG’s first cargo since the restart was being prepared for shipment to Japan. Alaska’s Pikka oil project, meanwhile, was described as almost finished, with management standing by guidance for a potential 30% production bump in 2026. Citi’s Tom Wallington pointed out that the cargo’s departure might “allay investor concerns” around the tricky commissioning period—the last stage before hitting full operations. Reuters

Beach Energy was last seen at A$1.167 on Friday, with Woodside closing out the session at about A$31.04. These two, along with Santos, serve as key benchmarks for locals tracking shifts in oil or LNG prices.

The trade looks shaky. Goldman Sachs flagged that Brent might slip to the low $70s before year-end. Their analysts say it would take a two-month shutdown in the Strait of Hormuz—a critical passageway for roughly 20% of the world’s oil and gas—to push their Q4 average forecast up to $93 a barrel from $71.

Santos isn’t done with internal shakeups. Back in February, the company announced plans to trim roughly 10% of its workforce and take a close look at its Australian oil and gas holdings after underlying profit tumbled 25% in 2025. Costs, project execution, and the asset mix are squarely in focus, with crude prices still offering some support for the shares.

Stock Market Today

  • Celestica (TSX:CLS) Valuation Assessed Amid Latest Share Price Surge
    April 18, 2026, 11:27 PM EDT. Celestica's stock (TSX:CLS) surged 3.5% in one day, marking a 47% increase over 30 days and a 30.9% rise year-to-date, driven largely by excitement around AI infrastructure demand. Analysts set a fair value near CA$570.53, roughly 5% above the recent closing price of CA$542.89, reflecting strong growth expectations. The company benefits from rising demand for advanced networking components from hyperscale clients, with ramp-ups in 800G and 1.6T technologies fueling revenue expansion. However, the stock trades at a high price-to-earnings ratio of 54.8x, above industry and peer averages, indicating optimism but less margin for error. Investors face a decision on whether the current price reflects undervaluation or market exuberance around Celestica's AI-driven future.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Why Cleveland-Cliffs Inc. Stock Sank Again: CLF Shares Lag Steel Peers in Friday Selloff
Previous Story

Why Cleveland-Cliffs Inc. Stock Sank Again: CLF Shares Lag Steel Peers in Friday Selloff

Gold Price Forecast: Bullion Falls Near $5,050 as Dollar Rises, but Banks Keep $6,200 Targets
Next Story

Gold Price Forecast: Bullion Falls Near $5,050 as Dollar Rises, but Banks Keep $6,200 Targets

Go toTop